Outlook Therapeutics to Engage Investors During Live Event
ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK) is set to showcase its progress and future plans during an upcoming Virtual Investor Lunch Break Event. Scheduled for June 25, this engaging event will kick off at 12:00 PM ET, providing a unique platform for the company to connect with investors and stakeholders alike.
Executive Insights and Discussion Highlights
During the event, attendees will gain a deeper understanding of the company’s commercial strategy directly from key executives. Chief Financial Officer and Interim Chief Executive Officer Lawrence Kenyon, Chief Commercial Officer Jeff Evanson, and Senior VP and Head of Europe Jedd Comiskey will lead the discussions, sharing insights on important upcoming milestones and ongoing company efforts.
One of the most exciting aspects of this event is the opportunity for live interaction. Investors and viewers will be encouraged to submit questions, allowing direct engagement with the company’s leadership team. This portion of the event aims to address as many inquiries as possible within the allotted time, creating a meaningful exchange between executives and the audience.
Accessing the Live Presentation
For those interested in participating, the Virtual Investor Lunch Break Event will be accessible via a live video webcast. This webcast can be found on the Events page under the Investors section of Outlook Therapeutics' official website, ensuring that interested parties can follow along with the discussion and insights shared.
A replay of the event will be made available two hours post-event, allowing for extended access. This replay will be available for a period of 90 days, enabling investors and other interested stakeholders to catch up on the discussions at their convenience.
About Outlook Therapeutics and Its Innovations
Outlook Therapeutics is dedicated to advancing the standard of care in ophthalmic medicine through the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma). Specifically focusing on enhancing treatment options for retinal diseases, the company has made significant strides with the launch of LYTENAVA™ in Germany and the United Kingdom, which has received marketing authorization for treating wet age-related macular degeneration (AMD).
In the United States, ONS-5010/LYTENAVA™ is still under investigation. A Biologics License Application (BLA) has been resubmitted to the FDA, and if approved, ONS-5010/LYTENAVA™ would be the first ophthalmic formulation of bevacizumab approved for treatment in retinal indications, such as wet AMD. This pioneering position could significantly change the landscape for patients requiring effective retinal therapies.
Contact Information for Investors
For any investor inquiries, contact Jenene Thomas, Chief Executive Officer at JTC Team, LLC. She can be reached at 908.824.0775 or via email at OTLK@jtcir.com. With the potential of ONS-5010/LYTENAVA™ in the market, investor interest is sure to grow, and questions about its innovative approach to treatment are more than welcome.
Frequently Asked Questions
What is the main purpose of the Virtual Investor Lunch Break Event?
The event aims to engage with investors, provide updates on commercial strategies, and answer live questions from the audience.
Who are the key executives participating in the event?
Lawrence Kenyon, Jeff Evanson, and Jedd Comiskey will lead the discussions during the event.
How can I access the live video webcast?
The webcast will be available on the Events page in the Investors section of Outlook Therapeutics' website.
Will there be an opportunity to ask questions during the event?
Yes, participants will be able to submit questions live, and the executives will address as many as possible.
What is ONS-5010/LYTENAVA™?
ONS-5010/LYTENAVA™ is a biopharmaceutical product aimed at improving treatment outcomes for retinal diseases.
